The Science of CJC-1295 Peptide: What Research Shows

If you're a qualified researcher studying endocrine function, metabolic signalling, or peptide biology, CJC-1295 peptide is a compound you've almost certainly encountered. At PeptideValidation.com, our research-grade CJC-1295 is supplied as a 5 mg lyophilized powder, intended strictly for controlled laboratory investigations into growth-hormone-releasing pathways. This article breaks down what the science actually says about CJC-1295, covering its structure, the DAC variant, documented observations, and what rigorous quality verification looks like for laboratories sourcing this peptide.

What Is the CJC-1295 Peptide?

CJC-1295 is a synthetic, 30-amino-acid analogue of growth-hormone-releasing hormone (GHRH) developed to study prolonged stimulation of the GH/IGF-1 axis in laboratory models. Unlike native GHRH, which has a plasma half-life of under 10 minutes, CJC-1295 incorporates four amino-acid substitutions that resist enzymatic degradation, extending its biological activity window significantly in preclinical studies.

Growth-hormone-releasing hormone (GHRH) is a 44-amino-acid peptide produced in the hypothalamus. It travels through the hypophyseal portal system and binds GHRH receptors on pituitary somatotrophs, triggering release of growth hormone (GH). The problem for researchers is that native GHRH degrades within minutes in plasma, making it difficult to study sustained GH-axis activation in vivo.

CJC-1295 was designed to solve that problem. By substituting four specific amino acids at positions 2, 8, 15, and 27, the peptide resists cleavage by dipeptidyl peptidase IV (DPP-IV) and other plasma proteases. The result is a research compound with a dramatically extended half-life compared to native GHRH.

In laboratory and early-phase studies, CJC-1295 has been shown to bind GHRH receptors with affinity comparable to the native hormone. That combination of receptor fidelity and protease resistance makes it a useful molecular tool for researchers examining sustained GH-axis signalling in controlled settings.

It is not a steroid. Researchers occasionally ask whether CJC-1295 is a steroid. The answer is clearly no. Steroids are lipid-derived molecules built on a four-ring carbon skeleton. CJC-1295 is a peptide, a chain of amino acids, with an entirely different chemical class, mechanism, and research profile. Conflating the two reflects a misunderstanding of basic biochemistry.

CJC-1295 With DAC: How the Variants Differ

CJC-1295 with DAC (Drug Affinity Complex) contains a maleimidopropionic acid (MPA) linker that covalently bonds the peptide to circulating albumin. This bonding extends the half-life to approximately 6 to 8 days in animal studies, compared to roughly 30 minutes for the non-DAC form, producing what researchers call a prolonged "GH bleed" rather than pulsatile release.

The DAC modification is one of the most studied structural differences in the GHRH-analogue literature. When CJC-1295 with DAC enters the bloodstream, its MPA linker reacts with the thiol group on cysteine-34 of serum albumin. Albumin has a plasma half-life of around 19 days in humans, so anything covalently attached to it effectively hitches a ride for an extended period.

What does that mean in practice for researchers? The two variants produce distinctly different GH-release profiles in preclinical models. The non-DAC form produces a sharper, shorter pulse of GH-axis activation, closer in kinetics to native GHRH but still substantially longer-lasting. The DAC form produces a sustained, lower-amplitude elevation across days.

Researchers studying pulsatile versus tonic GH signalling often select between these variants based on that kinetic difference. Correct CJC-1295 with DAC dosage protocols in research settings are typically based on body weight and administration interval, and published preclinical studies have used a range of concentrations depending on the model organism and endpoint being measured.

For laboratory sourcing, it's critical to confirm which form you're receiving. A batch-specific Certificate of Analysis (COA) should identify the exact compound, including the presence or absence of the DAC modification, verified by mass spectrometry. Receiving the wrong variant would invalidate experimental results. Always verify before you reconstitute.

What Preclinical Research Has Observed

Published preclinical studies report that CJC-1295 consistently elevates plasma GH and IGF-1 concentrations in rodent and primate models. Observed effects include changes in lean body composition, bone density markers, and lipid metabolism parameters, making it a studied tool in metabolic and endocrine research contexts.

A 2006 study published in the Journal of Clinical Endocrinology and Metabolism (Ionescu and Frohman) was among the first to characterize CJC-1295 pharmacokinetics in human subjects. Participants showed dose-dependent increases in mean plasma GH concentration, with effects persisting for up to 6 days following a single administration of the DAC form. IGF-1 levels rose proportionally and remained elevated for over a week.

Animal studies have explored downstream metabolic effects. In rodent models, sustained GH-axis activation from CJC-1295 administration correlated with reductions in fat mass, increases in lean tissue, and changes in lipid profiles. These observations are mechanistically consistent with known GH physiology, where GH promotes lipolysis and stimulates IGF-1-driven anabolic signalling in muscle and bone.

Researchers studying endocrine disorders, age-related GH decline, or metabolic syndrome pathways cite these properties as reasons CJC-1295 remains a relevant research compound. The peptide's capacity to produce measurable, reproducible GH-axis responses makes it a practical positive control or investigational agent in laboratory protocols.

CJC-1295 peptide benefits in a strict research context refer to its experimental utility: predictable receptor binding, measurable downstream markers, and now nearly two decades of published literature to draw comparisons from. That body of evidence is what makes it a scientifically credible research tool in 2026.

Documented Observations and Safety Profile in Studies

In published studies, CJC-1295 side effects most commonly reported include transient injection-site reactions, flushing, headache, and dizziness shortly after administration. These observations come from early-phase human pharmacokinetic studies. No severe adverse events were attributed to CJC-1295 at studied doses in the available literature, though the dataset remains limited.

The Ionescu and Frohman (2006) paper documented that most subjects experienced mild, short-lived adverse events, specifically water retention sensations, mild flushing, and brief headache. These are consistent with acute GH-axis activation and not unique to CJC-1295 among GHRH analogues.

CJC-1295 side effects observed in animal studies at supratherapeutic doses include changes in glucose metabolism, which aligns with known GH physiology. GH has counter-regulatory effects on insulin signalling, and researchers studying metabolic endpoints should account for glucose homeostasis as a confounding variable when designing protocols.

It's worth being direct: the clinical dataset for CJC-1295 in humans is small. Most published human data comes from a handful of early-phase pharmacokinetic studies. Animal data is more extensive but, as always, cross-species extrapolation requires caution. Researchers should review the available literature in full before designing any protocol involving this compound.

For laboratories working with CJC-1295 as a research peptide, the safety profile question is largely about compound purity rather than intrinsic peptide toxicity. A contaminated or incorrectly synthesised batch introduces variables that can confound results and, in cell culture work, cause cytotoxic effects unrelated to the peptide's actual biology. This is precisely why third-party HPLC purity data and mass spectrometry confirmation matter.

Quality Verification: What a Valid COA Must Include

A valid Certificate of Analysis for CJC-1295 peptide must include: peptide identity by mass spectrometry, HPLC purity (typically reported as a percentage area), peptide content by amino acid analysis or UV absorbance, batch and lot number, manufacturing date, storage conditions, and the name of the independent laboratory that performed the analysis.

PeptideValidation.com evaluates certified vendors against a structured set of criteria, and COA completeness is near the top of that list. Here's what a credible document looks like for CJC-1295 specifically.

Mass spectrometry (MS): The observed molecular weight should match the theoretical molecular weight of CJC-1295 within accepted instrument tolerance. For the DAC form, the albumin-reactive linker adds approximately 273 Da to the base peptide mass. If a supplier cannot provide MS data, that is a significant red flag.

HPLC purity: Research-grade peptides are generally expected to reach 98% purity or higher, measured by reversed-phase HPLC. The COA should show the chromatogram or at minimum the peak area percentage, not just a number on a label.

Batch traceability: Each lot should carry a unique identifier so researchers can trace any anomalous result back to a specific production run. Generic or reused lot numbers suggest weak quality management.

Independent third-party testing: In-house COAs from the same supplier that manufactured the peptide introduce an obvious conflict of interest. Third-party laboratory verification, where a separate facility with no commercial stake confirms the data, is the standard that serious research institutions expect.

When you source CJC-1295 peptide for your laboratory, verify each of these elements before your batch enters the freezer. Cutting corners on documentation is a protocol risk, not just a purchasing inconvenience.

Reconstitution, Storage, and Handling for Laboratory Use

CJC-1295 supplied as a lyophilized powder should be reconstituted with bacteriostatic water or sterile phosphate-buffered saline, added slowly down the vial wall to avoid foaming. Reconstituted peptide solution should be stored at 2 to 8 degrees Celsius and used within 28 days. Freeze-thaw cycles degrade peptide integrity and should be minimised.

The lyophilized form, the format in which PeptideValidation.com supplies research-grade CJC-1295 at 5 mg per vial, is the standard for long-term stability. Lyophilization removes water under vacuum, slowing the hydrolysis and oxidation reactions that degrade peptide structure over time. Kept dry and cold, unopened vials can maintain integrity for 24 months or longer, depending on storage conditions.

Reconstitution technique matters. Adding diluent too quickly, or shaking the vial, introduces air bubbles and mechanical shear that can disrupt peptide secondary structure. The standard practice is to inject the diluent slowly down the inner glass wall, then gently swirl, not vortex, until the powder dissolves completely. CJC-1295 is generally water-soluble and should dissolve without extended agitation.

Once reconstituted, the peptide solution is vulnerable to bacterial contamination and continued chemical degradation. Bacteriostatic water (0.9% benzyl alcohol) extends the usable window of reconstituted peptide to approximately 28 days under refrigeration. Standard sterile water without a preservative shortens that window considerably and is only practical for single-use preparations.

Document your reconstitution date, diluent volume, and calculated concentration on each vial. This is basic laboratory practice, but it directly affects experimental reproducibility. If a result looks anomalous, knowing the exact reconstitution conditions lets you rule out handling errors before questioning the compound itself.

Selecting a Research-Grade CJC-1295 Supplier in 2026

When evaluating a CJC-1295 peptide supplier, researchers should confirm: independent third-party COA availability, HPLC purity at or above 98%, mass spectrometry identity verification, transparent sourcing documentation, batch-specific lot traceability, and responsive technical support from staff with scientific backgrounds.

The peptide supply market has expanded considerably in recent years, and not all vendors operate to the same standard. For researchers who need reproducible data, supplier selection is a scientific decision, not just a purchasing one.

Peptide Validation Certified Vendors are assessed against objective criteria that mirror what institutional review boards and laboratory directors expect. Transparent sourcing, independent analytical testing, documented quality management systems, and consistent manufacturing practices are the baseline. Vendors who cannot provide batch-specific COAs on request, or who direct you to a generic document that isn't lot-specific, should be excluded from your supplier list.

CJC-1295 peptide price varies across the market, typically ranging from around $30 to over $100 per 5 mg vial depending on purity certification level, supplier overhead, and testing documentation provided. Price alone is a poor proxy for quality. A lower-cost vial with a complete, third-party-verified COA is a better research investment than an expensive vial with opaque documentation.

For the full framework on evaluating CJC-1295 quality, testing standards, and certified vendor criteria, see PeptideValidation.com's complete CJC-1295 research guide. It covers analytical methodology, COA interpretation, and the certification criteria applied to every vendor in the network.

Researchers studying growth-hormone-releasing pathways, endocrine axis dynamics, or metabolic peptide signalling will find that starting with a rigorously verified compound saves time, reduces confounding variables, and produces data you can stand behind.

Frequently asked questions

What is the CJC-1295 peptide used for in research?

In laboratory research, CJC-1295 peptide is used to study growth-hormone-releasing hormone (GHRH) receptor binding, sustained GH-axis activation, and downstream metabolic effects including changes in IGF-1, body composition markers, and lipid metabolism. It is a research compound intended for controlled scientific investigation only, not for human or veterinary use.

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 without DAC has a half-life of roughly 30 minutes in plasma and produces a pulsatile GH-release profile. CJC-1295 with DAC contains a maleimidopropionic acid linker that binds covalently to serum albumin, extending the half-life to approximately 6 to 8 days in animal studies and producing a sustained, lower-amplitude GH-axis response. Researchers select between these variants based on the kinetic profile their protocol requires.

Is CJC-1295 a steroid?

No. CJC-1295 is a peptide, a chain of 30 amino acids. Steroids are lipid-derived molecules built on a four-ring carbon skeleton with a completely different molecular structure and mechanism of action. CJC-1295 belongs to the GHRH-analogue class of synthetic peptides and shares no structural or pharmacological classification with anabolic steroids.

What CJC-1295 side effects have been observed in studies?

Early-phase human pharmacokinetic studies reported transient side effects including mild flushing, headache, dizziness, and injection-site reactions. Animal studies at higher doses noted changes in glucose metabolism consistent with GH physiology. The human clinical dataset is limited, and researchers should review available published literature carefully when designing protocols involving CJC-1295.

What purity level should research-grade CJC-1295 meet?

Research-grade CJC-1295 peptide is generally expected to meet at least 98% purity as measured by reversed-phase HPLC. The Certificate of Analysis should also include mass spectrometry identity confirmation, a unique batch lot number, manufacturing date, and the name of the independent third-party laboratory that conducted the analysis.

How should CJC-1295 lyophilized powder be stored and reconstituted?

Lyophilized CJC-1295 should be stored dry at minus 20 degrees Celsius until use. For reconstitution, add bacteriostatic water slowly down the inner vial wall and swirl gently. Do not shake or vortex. Reconstituted solution should be kept at 2 to 8 degrees Celsius and used within 28 days. Minimise freeze-thaw cycles to preserve peptide integrity.

Related in this series

• The Science of CJC-1295 Peptide: What Research Shows